149 related articles for article (PubMed ID: 35968338)
1. LMNB1, a potential marker for early prostate cancer progression.
Hong JH; Liang ST; Wang AS; Yeh CM; Huang HP; Sun CD; Zhang ZH; Lu SY; Chao YH; Chen CH; Pu YS
Am J Cancer Res; 2022; 12(7):3390-3404. PubMed ID: 35968338
[TBL] [Abstract][Full Text] [Related]
2. LMNB1 targets FOXD1 to promote progression of prostate cancer.
Huang Y; Zhang L; Liu T; Liang E
Exp Ther Med; 2023 Nov; 26(5):513. PubMed ID: 37840569
[TBL] [Abstract][Full Text] [Related]
3. Lamin B1 promotes tumor progression and metastasis in primary prostate cancer patients.
Luo F; Han J; Chen Y; Yang K; Zhang Z; Li J
Future Oncol; 2021 Feb; 17(6):663-673. PubMed ID: 33112662
[No Abstract] [Full Text] [Related]
4. Lamin B1 Overexpresses in Lung Adenocarcinoma and Promotes Proliferation in Lung Cancer Cells via AKT Pathway.
Li W; Li X; Li X; Li M; Yang P; Wang X; Li L; Yang B
Onco Targets Ther; 2020; 13():3129-3139. PubMed ID: 32346296
[TBL] [Abstract][Full Text] [Related]
5. High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.
Strand SH; Hoyer S; Lynnerup AS; Haldrup C; Storebjerg TM; Borre M; Orntoft TF; Sorensen KD
Clin Epigenetics; 2015; 7():111. PubMed ID: 26478752
[TBL] [Abstract][Full Text] [Related]
6. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy.
Kim SH; Park WS; Yun SI; Joo J; Joung JY; Seo HK; Chung J; Lee GK; Lee KH
Histopathology; 2016 Apr; 68(5):673-9. PubMed ID: 26272590
[TBL] [Abstract][Full Text] [Related]
9. Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy.
Kim SH; Park WS; Kim SH; Park B; Joo J; Lee GK; Joung JY; Seo HK; Chung J; Lee KH
PLoS One; 2016; 11(3):e0151646. PubMed ID: 26982980
[TBL] [Abstract][Full Text] [Related]
10. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
[TBL] [Abstract][Full Text] [Related]
11. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy.
Fajkovic H; Mathieu R; Lucca I; Hiess M; Hübner N; Al Hussein Al Awamlh B; Lee R; Briganti A; Karakiewicz P; Lotan Y; Roupret M; Rink M; Kluth L; Loidl W; Seitz C; Klatte T; Kramer G; Susani M; Shariat SF
Urol Oncol; 2016 May; 34(5):233.e1-6. PubMed ID: 26973136
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
[TBL] [Abstract][Full Text] [Related]
13. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
[TBL] [Abstract][Full Text] [Related]
14. Impact of surgical margin status on prostate-cancer-specific mortality.
Chalfin HJ; Dinizo M; Trock BJ; Feng Z; Partin AW; Walsh PC; Humphreys E; Han M
BJU Int; 2012 Dec; 110(11):1684-9. PubMed ID: 22788795
[TBL] [Abstract][Full Text] [Related]
15. Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression.
Saarinen I; Mirtti T; Seikkula H; Boström PJ; Taimen P
PLoS One; 2015; 10(10):e0140671. PubMed ID: 26469707
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens.
Yee DS; Shariat SF; Lowrance WT; Maschino AC; Savage CJ; Cronin AM; Scardino PT; Eastham JA
BJU Int; 2011 Aug; 108(4):502-7. PubMed ID: 21050364
[TBL] [Abstract][Full Text] [Related]
17. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report.
Pins MR; Fiadjoe JE; Korley F; Wong M; Rademaker AW; Jovanovic B; Yoo TK; Kozlowski JM; Raji A; Yang XJ; Lee C
Prostate Cancer Prostatic Dis; 2004; 7(3):243-8. PubMed ID: 15343364
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of LMNB1 Inhibits the Proliferation of Lung Adenocarcinoma Cells by Inducing DNA Damage and Cell Senescence.
Li J; Sun Z; Cui Y; Qin L; Wu F; Li Y; Du N; Li X
Front Oncol; 2022; 12():913740. PubMed ID: 35712471
[TBL] [Abstract][Full Text] [Related]
19. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
20. A pan-cancer analysis based on weighted gene co-expression network analysis identifies the biomarker utility of lamin B1 in human tumors.
Hua Y; He Z; Zhang X
Cancer Biomark; 2022; 34(1):23-39. PubMed ID: 34511484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
